
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
BD Pharmingen™ Purified Mouse Anti-Human IgE
Clone G7-26 (RUO)


Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Recommended Assay Procedures
For current recommendations of pairing mAbs to be used in two-site quantitative ELISA, please refer to the product information sheet under "ELISA and ELISPOT" at our website: http://www.bdbiosciences.com/us/s/resources.
Product Notices
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Sodium azide is a reversible inhibitor of oxidative metabolism; therefore, antibody preparations containing this preservative agent must not be used in cell cultures nor injected into animals. Sodium azide may be removed by washing stained cells or plate-bound antibody or dialyzing soluble antibody in sodium azide-free buffer. Since endotoxin may also affect the results of functional studies, we recommend the NA/LE (No Azide/Low Endotoxin) antibody format, if available, for in vitro and in vivo use.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
The G7-26 monoclonal antibody specifically recognizes the constant region of human Immunoglobulin E (IgE). It does not crossreact with other immunoglobulin heavy chain isotypes. IgE exists in a transmembrane form that is expressed by B lymphocytes and serves as an antigen receptor. Soluble IgE is produced and secreted by activated B cells and plasma cells. IgE may bind through its constant region to cell surface receptors, such as the high-affinity (FcεRI) or low-affinity (FcεRII/CD23) receptors for IgE. FcεRI is expressed on mast cells, basophils, and at lower levels, on dendritic cells and monocytes. FcεRII/CD23 is expressed by B cells and by some other cell types including T cells, monocytes, eosinophils, neutrophils, follicular dendritic cells, and Langerhans cells. Crosslinking of Fc receptor-bound IgE antibodies by multivalent antigens or allergens can induce phagocytosis or the cellular release of inflammatory mediators. Although IgE can provide immune protection against pathogenic parasites, it may also play a central role in a variety of allergic disorders.
Development References (4)
-
Böhm I, Speck U, Schild HH. Pilot study on basophil activation induced by contrast medium.. Fundam Clin Pharmacol. 2011; 25(2):267-76. (Methodology). View Reference
-
Cheng YX, Foster B, Holland SM, et al. CD2 identifies a monocyte subpopulation with immunoglobulin E-dependent, high-level expression of Fc epsilon RI.. Clin Exp Allergy. 2006; 36(11):1436-45. (Biology). View Reference
-
Foster B, Metcalfe DD, Prussin C. Human dendritic cell 1 and dendritic cell 2 subsets express FcepsilonRI: correlation with serum IgE and allergic asthma.. J Allergy Clin Immunol. 2003; 112(6):1132-8. (Biology). View Reference
-
Kubota T, Mukai K, Minegishi Y, Karasuyama H. Different stabilities of the structurally related receptors for IgE and IgG on the cell surface are determined by length of the stalk region in their alpha-chains.. J Immunol. 2006; 176(11):7008-14. (Clone-specific). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.